# A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

> **NCT02671435** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **MedImmune LLC** · enrollment: 383 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Monalizumab
- **DRUG:** Durvalumab
- **DRUG:** Cetuximab
- **DRUG:** mFOLFOX6
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT02671435
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-02-22
- **Primary completion:** 2021-10-26
- **Final completion:** 2025-09-01
- **Target enrollment:** 383 (ACTUAL)
- **Last updated:** 2025-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02671435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02671435, "A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02671435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*